Bio/Pharma Business

A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

The Global Reporting Initiative begins an effort to increase the level and strength of sustainability reporting among US-based corporations.

The prevention and treatment of noncommunicable diseases is becoming an increasingly important consideration in global health initiatives.

An annual analysis rates the performance of pharmaceutical and biotechnology companies in corporate sustainability.

World leaders gathered at the United Nations last month to review the progress and map out a strategy for achieving the Millennium Development Goals.

A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

A look at MVI's malaria work in developing countries.

Despite the poor economic climate, large-scale mergers and acquisitions in the pharmaceutical industry struck back with a vengeance in 2009.

An upcoming summit will assess the progress and gaps in realizing the UN Millennium Development Goals, including outcomes from global health initiatives.

A roundup of developments on corporate social responsibility from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Secretary of State Hillary Clinton details the progress and future direction of the US role in the Global Health Initiative.

The UN Global Compact, a corporate-social-responsibility initiative, releases a management model to help businesses implement sustainability principles.

A roundup of developments on corporate social responsibility from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

A recently released study by Accenture shows that sustainability is becoming an increasingly important part of the strategies and operations of companies.

The health of the contract-services industry is improving but the market is signaling tougher competition ahead. This article is part of the 2010 Outsourcing Resources special issue.

A roundup of developments on corporate social responsibility from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Led by sustainability efforts by Walmart, a new tool emerges for quickly evaluating the environmental and human-health profile of formulated products.

Acumen Fund, a nonprofit venture-capital fund, uses patient capital to build economically sustainable businesses involved in poverty alleviation.

The American Association for the Advancement of Science rolls out several initiatives to increase partnerships and communication on human rights between scientific groups and between scientific and human rights groups.

A roundup of developments on corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other organizations.

Tablets and capsules are mainstay product forms, so what are the spending and innovation trends for solid-dosage manufacturing equipment and machinery?

T cell therapy is an investigational approach that is being assessed for the patient?specific treatment of cancer.

The second annual Pharmaceutical Technology Bioprocessing Survey offers a snapshot of the industry following 2009's megamergers.

The University of California, San Francisco (CA, USA; UCSF) has signed an agreement with Genentech with the aim of discovering and developing drug candidates for neurodegenerative diseases.

The Director of Operations at a security firm explains pharma's need for intelligence and security.

The contract services industry may not be as robust in 2009 as it has been in previous years, but it's not as bad as many people think.

A Pharmaceutical Technology report looks at trends in biopharmaceutical manufacturing. This article contains bonus online-exclusive material.

The world's top 50 pharmaceutical companies accounted for prescription drug sales of $558 billion (413 billion euro) in 2008.

Patent infringement claims and a lack of clear global trade distribution routes may be unraveling the country's generic-drug export industry.

Despite the market downturn and financial meltdown, private equity investors are lining up for pharmaceutical services businesses.